HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Runx1 Deficiency Protects Against Adverse Cardiac Remodeling After Myocardial Infarction.

AbstractBACKGROUND:
Myocardial infarction (MI) is a leading cause of heart failure and death worldwide. Preservation of contractile function and protection against adverse changes in ventricular architecture (cardiac remodeling) are key factors to limiting progression of this condition to heart failure. Consequently, new therapeutic targets are urgently required to achieve this aim. Expression of the Runx1 transcription factor is increased in adult cardiomyocytes after MI; however, the functional role of Runx1 in the heart is unknown.
METHODS:
To address this question, we have generated a novel tamoxifen-inducible cardiomyocyte-specific Runx1-deficient mouse. Mice were subjected to MI by means of coronary artery ligation. Cardiac remodeling and contractile function were assessed extensively at the whole-heart, cardiomyocyte, and molecular levels.
RESULTS:
Runx1-deficient mice were protected against adverse cardiac remodeling after MI, maintaining ventricular wall thickness and contractile function. Furthermore, these mice lacked eccentric hypertrophy, and their cardiomyocytes exhibited markedly improved calcium handling. At the mechanistic level, these effects were achieved through increased phosphorylation of phospholamban by protein kinase A and relief of sarco/endoplasmic reticulum Ca2+-ATPase inhibition. Enhanced sarco/endoplasmic reticulum Ca2+-ATPase activity in Runx1-deficient mice increased sarcoplasmic reticulum calcium content and sarcoplasmic reticulum-mediated calcium release, preserving cardiomyocyte contraction after MI.
CONCLUSIONS:
Our data identified Runx1 as a novel therapeutic target with translational potential to counteract the effects of adverse cardiac remodeling, thereby improving survival and quality of life among patients with MI.
AuthorsCharlotte S McCarroll, Weihong He, Kirsty Foote, Ashley Bradley, Karen Mcglynn, Francesca Vidler, Colin Nixon, Katrin Nather, Caroline Fattah, Alexandra Riddell, Peter Bowman, Elspeth B Elliott, Margaret Bell, Catherine Hawksby, Scott M MacKenzie, Liam J Morrison, Anne Terry, Karen Blyth, Godfrey L Smith, Martin W McBride, Thomas Kubin, Thomas Braun, Stuart A Nicklin, Ewan R Cameron, Christopher M Loughrey
JournalCirculation (Circulation) Vol. 137 Issue 1 Pg. 57-70 (01 02 2018) ISSN: 1524-4539 [Electronic] United States
PMID29030345 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)
Copyright© 2017 The Authors.
Chemical References
  • Calcium-Binding Proteins
  • Core Binding Factor Alpha 2 Subunit
  • Runx1 protein, mouse
  • phospholamban
  • Cyclic AMP-Dependent Protein Kinases
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases
Topics
  • Animals
  • Calcium Signaling
  • Calcium-Binding Proteins (metabolism)
  • Cells, Cultured
  • Core Binding Factor Alpha 2 Subunit (deficiency, genetics)
  • Cyclic AMP-Dependent Protein Kinases (metabolism)
  • Disease Models, Animal
  • Mice, Inbred C57BL
  • Mice, Knockout
  • Myocardial Contraction
  • Myocardial Infarction (genetics, metabolism, pathology, physiopathology)
  • Myocytes, Cardiac (metabolism, pathology)
  • Phosphorylation
  • Rabbits
  • Sarcoplasmic Reticulum (metabolism, pathology)
  • Sarcoplasmic Reticulum Calcium-Transporting ATPases (metabolism)
  • Time Factors
  • Ventricular Function, Left
  • Ventricular Remodeling

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: